AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32073177 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75-125 mg)
Number of subjects: 60
Study 32073177 — intervention group
Group type: COMPARATOR
Intervention: Placebo/active control (0-40 mg of MDMA)
Number of subjects: 60
Study 35915477 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency vibration associated with cryotherapy for 30 s before and during vaccine administration
Number of subjects: 350
Study 35915477 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol of vaccine administration (Control group)
Number of subjects: 350
Study 35915477 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency vibration associated with cryotherapy
Number of subjects: 350
Study 34083744 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone/bupropion (NB)
Number of subjects: 1317
Study 34083744 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 1317
Study 32093546 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Self‐reflection intervention
Number of subjects: 121
Study 32093546 — intervention group
Group type: COMPARATOR
Intervention: Disengagement control group
Number of subjects: 121
Study 34259193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (SQT): esomeprazole 20 mg twice daily for 10 days, amoxicillin 1000 mg twice daily for 5 days, clarithromycin 500 mg and tinidazole 500 mg twice daily for 5 days
Number of subjects: 170
Study 34259193 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (STT): esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 14 days
Number of subjects: 170
Study 32785636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg)
Number of subjects: 38
Study 32785636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32785636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (any dose)
Number of subjects: 38
Study 36302533 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone combined with DL-3-N-butylphthalide (NBP)
Number of subjects: 86
Study 36302533 — intervention group
Group type: COMPARATOR
Intervention: Edaravone only
Number of subjects: 86
Study 32870473 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab combined with nanoparticle albumin‐bound (nab)‐paclitaxel
Number of subjects: 0
Study 32870473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 34037740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 34037740 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36380519 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Motivational Interviewing (MMI) intervention
Number of subjects: 94
Study 36380519 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 33338078 — intervention group
Group type: EXPERIMENTAL
Intervention: Service users’ experiences of ALRTIs and healthcare services
Number of subjects: 29
Study 33338078 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance approach to prescribing
Number of subjects: 29
Study 33338078 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for service users to become reliable, subjective and agentic experts of their health
Number of subjects: 29
Study 33338078 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging power structures within healthcare, political and economic institutions
Number of subjects: 29
Study 34550076 — intervention group
Group type: EXPERIMENTAL
Intervention: VB+FC (Virtual Badges + Facilitator Contact)
Number of subjects: 602
Study 34550076 — intervention group
Group type: EXPERIMENTAL
Intervention: VB+FC and VB+FC+online discussion board
Number of subjects: 602
Study 34550076 — intervention group
Group type: EXPERIMENTAL
Intervention: VB (Virtual Badges)
Number of subjects: 602
Study 34550076 — intervention group
Group type: COMPARATOR
Intervention: Intervention only conditions
Number of subjects: 602
Study 33115428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing (PGx) for antidepressant prescribing
Number of subjects: 31
Study 33969614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 711
Study 33969614 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone (control)
Number of subjects: 711
Study 32091668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 16328
Study 32091668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with routine GPI
Number of subjects: 16328
Study 32091668 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 16328
Study 36253920 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHWs) as patient-site facilitators
Number of subjects: 28
Study 36253920 — intervention group
Group type: COMPARATOR
Intervention: Control group with trained university student facilitators
Number of subjects: 28
Study 36253920 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHWs) group
Number of subjects: 28
Study 33500177 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic Townsend deprivation index (TDI)
Number of subjects: 501882
Study 33500177 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide gene-by-environment interaction study
Number of subjects: 501882
Study 35907824 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT (Avelle, Convatec™) applied to the perineal wound
Number of subjects: 21
Study 35907824 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical cohort)
Number of subjects: 21
Study 34366631 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Xiaochaihu Decoction (MXD) plus omeprazole simulation
Number of subjects: 288
Study 34366631 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole plus herbs simulation
Number of subjects: 288
Study 35045208 — intervention group
Group type: EXPERIMENTAL
Intervention: LC51‐0255 (0.25, 0.5, 1, 2, or 4 mg)
Number of subjects: 50
Study 35045208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35045208 — intervention group
Group type: EXPERIMENTAL
Intervention: LC51‐0255
Number of subjects: 50
Study 35172273 — intervention group
Group type: EXPERIMENTAL
Intervention: StemPrintER Risk Score (SPRS)
Number of subjects: 776
Study 35172273 — intervention group
Group type: COMPARATOR
Intervention: Oncotype DX Recurrence Score (RS)
Number of subjects: 776
Study 35172273 — intervention group
Group type: EXPERIMENTAL
Intervention: StemPrintER Risk Score (SPRS) with Clinical Treatment Score (CTS)
Number of subjects: 776
Study 35172273 — intervention group
Group type: COMPARATOR
Intervention: Oncotype DX Recurrence Score (RS) with Clinical Treatment Score (CTS)
Number of subjects: 776
Study 35172273 — intervention group
Group type: EXPERIMENTAL
Intervention: StemPrintER Risk Score (SPRS) in node-negative patients with Clinical Treatment Score (CTS)
Number of subjects: 776
Study 35172273 — intervention group
Group type: COMPARATOR
Intervention: Oncotype DX Recurrence Score (RS) in node-negative patients with Clinical Treatment Score (CTS)
Number of subjects: 776
Study 35172273 — intervention group
Group type: EXPERIMENTAL
Intervention: StemPrintER Risk Score (SPRS) for late (5-10 years) distant recurrence (DR) prognostication
Number of subjects: 776
Study 35172273 — intervention group
Group type: COMPARATOR
Intervention: Oncotype DX Recurrence Score (RS) for late (5-10 years) distant recurrence (DR) prognostication
Number of subjects: 776
Study 34087542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring the comment
Number of subjects: 156
Study 34087542 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassuring
Number of subjects: 156
Study 34087542 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating
Number of subjects: 156
Study 34087542 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging
Number of subjects: 156
Study 34087542 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 156
Study 35373443 — intervention group
Group type: COMPARATOR
Intervention: Active Monitoring (AM)
Number of subjects: 2565
Study 35373443 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy (RP)
Number of subjects: 2565
Study 35373443 — intervention group
Group type: EXPERIMENTAL
Intervention: External-Beam Radiotherapy (EBRT)
Number of subjects: 2565
Study 35373443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose-Rate Brachytherapy (BT)
Number of subjects: 2565
Study 33300961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Vistusertib
Number of subjects: 0
Study 33300961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Everolimus
Number of subjects: 0
Study 33300961 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant alone
Number of subjects: 0
Study 35901408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 0
Study 35901408 — intervention group
Group type: COMPARATOR
Intervention: Cannabis abstinence
Number of subjects: 0
Study 34228510 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA)‐guided intervention
Number of subjects: 541
Study 33750092 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin as primary anticoagulant
Number of subjects: 79
Study 33750092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of assays to monitor heparin therapy
Number of subjects: 79
Study 33750092 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic tests
Number of subjects: 79
Study 33750092 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin replacement
Number of subjects: 79
Study 33750092 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion thresholds
Number of subjects: 79
Study 33750092 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in a randomized controlled trial
Number of subjects: 79
Study 33116241 — intervention group
Group type: EXPERIMENTAL
Intervention: High density microarray patches (MAP)
Number of subjects: 12
Study 35067772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis drops (first 6 weeks)
Number of subjects: 6
Study 35067772 — intervention group
Group type: COMPARATOR
Intervention: Cannabis oil drops (first 6 weeks)
Number of subjects: 6
Study 35067772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis drops (last 6 weeks)
Number of subjects: 6
Study 35067772 — intervention group
Group type: COMPARATOR
Intervention: Cannabis oil drops (last 6 weeks)
Number of subjects: 6
Study 35067772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis drops
Number of subjects: 6
Study 35067772 — intervention group
Group type: COMPARATOR
Intervention: Cannabis oil drops
Number of subjects: 6
Study 32992075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose prophylactic anticoagulation
Number of subjects: 600
Study 32992075 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose prophylactic anticoagulation
Number of subjects: 600
Study 32992075 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 600
Study 32992075 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for atorvastatin
Number of subjects: 600
Study 35942505 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 980
Study 35942505 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 980
Study 34225698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic light intervention (daytime blue-enriched white light, CCT > 5000 K and blue-depleted light < 3000 K, 3 hours prior to sleep)
Number of subjects: 24
Study 34225698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic light intervention
Number of subjects: 24
Study 35811080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin for 3 days
Number of subjects: 89
Study 35811080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 32690406 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 80
Study 32690406 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking
Number of subjects: 80
Study 32690406 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 80
Study 32919516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 0
Study 32919516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35585641 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg)
Number of subjects: 0
Study 35585641 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33252490 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg)
Number of subjects: 108
Study 33252490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 32622585 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36436076 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular brachial plexus block (CC group)
Number of subjects: 56
Study 36436076 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular brachial plexus block (SC group)
Number of subjects: 56
Study 34180574 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5% hydrogen peroxide (37.5HP) in-office bleaching with two 8-min applications/clinical session
Number of subjects: 40
Study 34180574 — intervention group
Group type: COMPARATOR
Intervention: 37.5% hydrogen peroxide (37.5HP) in-office bleaching with three 8-min applications/clinical session
Number of subjects: 40
Study 34180574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (two and three applications)
Number of subjects: 40
Study 33268603 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection (DP)
Number of subjects: 194
Study 33268603 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 194
Study 35405965 — intervention group
Group type: EXPERIMENTAL
Intervention: Green mandarin extract (PTE) 300 mg/day for 12 weeks
Number of subjects: 0
Study 35405965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35702003 — intervention group
Group type: EXPERIMENTAL
Intervention: MIHOW (Maternal Infant Health Outreach Worker program)
Number of subjects: 132
Study 35702003 — intervention group
Group type: COMPARATOR
Intervention: Minimal Education Intervention (MEI)
Number of subjects: 132
Study 32952034 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lecture utilizing metaphoric radiology signs
Number of subjects: 49
Study 32952034 — intervention group
Group type: COMPARATOR
Intervention: Control lecture without metaphoric signs
Number of subjects: 49
Study 32234247 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min rounding intervention
Number of subjects: 41
Study 32234247 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 32234247 — intervention group
Group type: EXPERIMENTAL
Intervention: All aged care sites (combined data)
Number of subjects: 41
Study 32234247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 41
Study 36190186 — intervention group
Group type: EXPERIMENTAL
Intervention: dd-cfDNA
Number of subjects: 280
Study 36190186 — intervention group
Group type: EXPERIMENTAL
Intervention: DSA
Number of subjects: 280
Study 36190186 — intervention group
Group type: COMPARATOR
Intervention: Both dd-cfDNA and DSA
Number of subjects: 280
Study 32857210 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective removal (SE)
Number of subjects: 74
Study 32857210 — intervention group
Group type: COMPARATOR
Intervention: Stepwise removal (SW)
Number of subjects: 74
Study 32348796 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward comparison (participants told they received a worse meal)
Number of subjects: 0
Study 32348796 — intervention group
Group type: COMPARATOR
Intervention: Control comparison (participants told they received the same meal)
Number of subjects: 0
Study 32348796 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward comparison (participants told they received a better meal)
Number of subjects: 0
Study 35313112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmologic procedures
Number of subjects: 806
Study 35313112 — intervention group
Group type: COMPARATOR
Intervention: Control period (8-day period 30 days earlier)
Number of subjects: 806
Study 33809277 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized telerehabilitation intervention after hospital discharge
Number of subjects: 0
Study 33809277 — intervention group
Group type: COMPARATOR
Intervention: Standard health education and/or care in a rehabilitation center
Number of subjects: 0
Study 32490272 — intervention group
Group type: EXPERIMENTAL
Intervention: High socio-environmental status
Number of subjects: 2445
Study 32490272 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 2445
Study 32490272 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic level
Number of subjects: 2445
Study 35794120 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises + Kinesio taping
Number of subjects: 58
Study 35794120 — intervention group
Group type: COMPARATOR
Intervention: Exercises + Analgesic current
Number of subjects: 58
Study 34034400 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with suplatast tosilate, started 2 weeks before pollen season.
Number of subjects: 34
Study 34034400 — intervention group
Group type: COMPARATOR
Intervention: Control group with no prophylactic treatment.
Number of subjects: 34
Study 34034400 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with suplatast tosilate.
Number of subjects: 34
Study 35270768 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning group (face-to-face intervention + gamified e-learning module)
Number of subjects: 65
Study 35270768 — intervention group
Group type: COMPARATOR
Intervention: Control group (gamified e-learning module only)
Number of subjects: 65
Study 35270768 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning group
Number of subjects: 65
Study 33322161 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative educational intervention program
Number of subjects: 224
Study 33322161 — intervention group
Group type: COMPARATOR
Intervention: Routine management without educational program (Control)
Number of subjects: 224
Study 32796417 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT)
Number of subjects: 38
Study 32796417 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 38
Study 33217805 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 0
Study 33217805 — intervention group
Group type: COMPARATOR
Intervention: Sham kinesio taping (sham KT)
Number of subjects: 0
Study 33277736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled self-management intervention (4Ds)
Number of subjects: 0
Study 33277736 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 33114364 — intervention group
Group type: EXPERIMENTAL
Intervention: WS group 1 (500 mL purified water)
Number of subjects: 64
Study 33114364 — intervention group
Group type: EXPERIMENTAL
Intervention: WS group 2 (200 mL purified water)
Number of subjects: 64
Study 33114364 — intervention group
Group type: EXPERIMENTAL
Intervention: WS group 3 (100 mL purified water)
Number of subjects: 64
Study 33114364 — intervention group
Group type: COMPARATOR
Intervention: NW group (no water supplementation)
Number of subjects: 64
Study 34423506 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional correction training based on FMS scores in Group A
Number of subjects: 420
Study 34423506 — intervention group
Group type: COMPARATOR
Intervention: No intervention measures in Group B
Number of subjects: 420
Study 34423506 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional correction training in Group A
Number of subjects: 420
Study 32275060 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS-TC transitional care model
Number of subjects: 19
Study 34321046 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational films intervention
Number of subjects: 10000
Study 33028223 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative walking intervention with remote coaching and pedometer
Number of subjects: 120
Study 33028223 — intervention group
Group type: COMPARATOR
Intervention: General walking advice (Control)
Number of subjects: 120
Study 35785477 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week dietary weight-loss intervention
Number of subjects: 52
Study 33493551 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood (WB) method
Number of subjects: 664
Study 33493551 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells (PBMC) method
Number of subjects: 664
Study 33454114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic cleaning
Number of subjects: 48
Study 33454114 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking
Number of subjects: 48
Study 33454114 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiping
Number of subjects: 48
Study 34118426 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive recruitment (approaching recently seen eligible patients in consecutive order by date seen)
Number of subjects: 0
Study 34118426 — intervention group
Group type: COMPARATOR
Intervention: Traditional recruitment (such as posters, flyers, tear‐offs)
Number of subjects: 0
Study 34118426 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 32414353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic/likely pathogenic variant in a gene associated with adult-onset disease
Number of subjects: 0
Study 32414353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic/likely pathogenic variant in a gene associated with pediatric-onset disease or with risk reduction interventions that begin in childhood
Number of subjects: 0
Study 32414353 — intervention group
Group type: COMPARATOR
Intervention: No apparent genomic result, sex- and age-matched to Groups 1 and 2
Number of subjects: 0